

Supplementary Information for

**Ruthenium-Catalyzed Formal sp³-H Activation of Allylsilanes/esters
with Olefins: Efficient Access to functionalized 1,3-Dienes**

Dattatraya H. Dethe^{*a}, Nagabhushana C B^a, Saikat Das^{a,†}, Appasaheb Nirpal^{a†}

^aDepartment of Chemistry, Indian Institute of Technology-Kanpur, Kanpur - 208016, India.
Tel: + 91-512-2596537, fax: + 91-512-2597436.

Table of Contents


1. General Information:.....	3
2. Experimental procedures	
2.1. General procedure for the oxidative coupling reaction of allyl esters with acrylates	
2.1a. Examples with data	4 - 8
2.1b. Procedure and data for isomerization of Allylsilanes and Deuterated study.....	9
2.1c. Coupling reaction between vinylsilane 6b and methyl acrylate 2a	9-10
2.1d. Procedure and data for Diels-Alder reaction, 8	10
2.2.Gram scale synthesis and its applications.....	10 - 12
2.2a. Synthesis of compound 5gh	
2.2b. Synthesis of compound 9	
2.2c. Synthesis of compound 13	
2.2d. Synthesis of compound 11	
2.2e. Synthesis of compound 12	
2.2f. Synthesis of compound 10	
2.3.Total synthesis of norpyrenophorin.....	12-14
2.3a. Synthesis of compound 19	
2.3b. Synthesis of compound 20	
2.3c. Synthesis of compound 21	
2.3d. Synthesis of compound 22	
2.3e. Synthesis of norpyenophorin 14	
3. NMR spectra.....	15 - 68
4. References.....	69

1. General Information:

General Aspects: Experiments involving moisture and/or air sensitive components were performed in oven-dried glassware. Commercial solvents and reagents were used without further purification unless otherwise noted. All the chemicals were purchased commercially, and used without further purification. Yields refer to chromatographically pure compounds, unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm Merck silica gel plates (60F-254) using UV light as a visualizing agent and an p-anisaldehyde or ninhydrine stain, and heat as developing agents. Merck silica gel (particle size 100-200 and 230-400 mesh) was used for flash column chromatography. Neat compounds were used for record IR spectra. NMR spectra were recorded on either a Bruker Avance 400 (1H, 400 MHz; 13C, 100 MHz), Bruker Avance 500 (1H, 500 MHz; 13C, 125 MHz), or JEOL DELTA (ECX) 500 (1H, 500 MHz; 13C, 125 MHz). Mass spectrometric data were obtained using WATERS-Q-Tof-Premier-HAB213 and WATERS-QTof-Premier-ESI-MS instruments. Optical rotations were measured using a polarimeter (AUTOPOL II) at 30 °C. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, spt= septet, dd = doublet of doublet, ddd = doublet of a doublet of a doublet, dt = doublet of a triplet, td = triplet of a doublet, m = multiplet, br = broad.

2. Experimental Procedures:


2.1. General procedure for the oxidative coupling reaction of allylsilanes/esters with activated olefins



A 8 mL screw-cap vial was charged with $[\text{RuCl}_2(\text{p-cymene})]_2$ (6.1 mg, 0.01 mmol, 5.0 mol%), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (80 mg, 0.4 mmol, 2.0 equiv), AgSbF_6 (14 mg, 0.04 mmol, 20 mol%) and 1,2-dichloroethane (2.0 mL). Then acrylate/vinyl sulfone (0.2 mmol, 1.0 equiv) and allylsilane or allyl ester (0.24 mmol, 1.2 equiv) were added into the solution in sequence. The vial was sealed under N_2 and heated to 80°C with stirring for 16 h. After cooling down, the mixture was diluted with ethyl acetate, filtrated and concentrated to give the crude compound which was directly purified by column chromatography.


2.1a. Examples with data

Compound 3aa Following general procedure, **3aa** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (33 mg, 0.16 mmol, 82%). ^1H NMR (400MHz, CDCl_3) δ 7.38 (d, $J = 15.9$ Hz, 1H), 6.56 (q, $J = 7.2$ Hz, 1H), 5.79 (d, $J = 15.7$ Hz, 1H), 3.70 (s, 3H), 1.88 (d, $J = 7.2$ Hz, 3H), 0.21 (s, 9H). ^{13}C NMR (125MHz, CDCl_3) δ 167.9, 152.2, 146.2, 138.3, 116.7, 51.4, 18.3, 0.5 (3C). HRMS (ESI) m/z calcd. for $\text{C}_{10}\text{H}_{18}\text{O}_2\text{Si}$ $[\text{M}+\text{H}]^+$ 199.1154; found 199.1158. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2970, 2950, 1743, 1712, 1643, 1618, 1432, 1300, 1115, 910, 840.




NOESY shows that H_a (0.21) and H_b (1.88) are correlated and also H_c (6.56) and H_d (7.38) are weakly correlated.


Compound 3ab Following general procedure, **3ab** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (40 mg, 0.168 mmol, 84%). ^1H NMR (400MHz, CDCl_3) δ 7.38 (d, $J = 15.9$ Hz, 1H), 6.57 (q, $J = 7.2$ Hz, 1H), 5.79 (d, $J = 15.5$ Hz, 1H), 4.12 (t, $J = 6.4$ Hz, 2H), 1.89 (d, $J = 7.2$ Hz, 3H), 1.67 - 1.61 (m, 2H), 1.42 - 1.35 (m, 2H), 0.93 (t, $J = 7.3$ Hz, 3H), 0.22 (s, 9H). ^{13}C NMR (100MHz, CDCl_3) δ 167.6, 151.8, 146.1, 138.3, 117.2, 64.1, 30.9, 19.3, 18.4, 13.8, 0.5 (3C). HRMS (ESI) m/z calcd. for $\text{C}_{13}\text{H}_{24}\text{O}_2\text{Si}$ $[\text{M}+\text{H}]^+$ 241.1624; found 241.1626. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2975, 2948, 1749, 1716, 1640, 1619, 1430, 1298, 1120, 908, 838.




Compound 3ac Following general procedure, **3ac** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (38 mg, 0.158 mmol, 79%). ^1H NMR (400MHz, CDCl_3) δ 7.39 (d, $J = 15.9$ Hz, 1H), 6.58 (q, $J = 7.2$ Hz, 1H), 5.81 (d, $J = 15.3$ Hz, 1H), 3.91 (d, $J = 6.4$ Hz, 2H), 2.00 - 1.94 (m, 1H), 1.89 (d, $J = 7.0$ Hz, 3H), 0.94 (d, $J = 6.5$ Hz, 6H), 0.23 (s, 9H). ^{13}C NMR (125MHz, CDCl_3) δ 167.5, 151.8, 145.8, 138.4, 117.2, 70.4, 27.9, 19.2 (2C), 18.3, 0.5 (3C). HRMS (ESI) m/z calcd. for $\text{C}_{13}\text{H}_{24}\text{O}_2\text{Si}$ $[\text{M}+\text{H}]^+$ 241.1624; found 241.1626. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2978, 2949, 1748, 1716, 1642, 1622, 1431, 1297, 1122, 906, 839.




Compound 3ad Following general procedure, **3ad** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (42 mg, 0.16 mmol, 80%). ^1H NMR (400MHz, CDCl_3) δ 7.37 (d, $J = 15.9$ Hz, 1H), 6.57 (q, $J = 7.2$ Hz, 1H), 5.78 (d, $J = 15.3$ Hz, 1H), 4.83 - 4.76 (m, 1H), 1.88 (d, $J = 7.3$ Hz, 3H), 1.76 - 1.71 (m, 2H), 1.43 (d, $J = 9.8$ Hz, 2H), 1.38 - 1.34 (m, 2H), 0.22 (s, 9H). ^{13}C NMR (100MHz, CDCl_3) δ 166.9, 151.5, 145.9, 138.3, 117.7, 72.3, 31.8 (2C), 25.5, 23.9 (2C), 18.4, 0.5 (3C). HRMS (ESI) m/z calcd. for $\text{C}_{15}\text{H}_{26}\text{O}_2\text{Si}$ $[\text{M}+\text{H}]^+$ 267.1780; found 267.1783. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2983, 2953, 1743, 1708, 1636, 1620, 1439, 1293, 1115, 902, 832.



Compound 3ae Following general procedure, **3ae** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (54 mg, 0.150 mmol, 71%). ^1H NMR (500MHz, CDCl_3) δ 7.38 (d, $J = 15.9$ Hz, 1H), 6.57 (q, $J = 7.2$ Hz, 1H), 6.37 (d, $J = 6.9$ Hz, 1H), 6.11 (dd, $J = 6.9, 5.2$ Hz, 1H), 5.81 - 5.78 (m, 2H), 4.15 - 4.12 (m, 4H), 1.89 (d, $J = 7.4$ Hz, 3H), 1.65 (m, 6H), 1.37 - 1.33 (m, 8H), 0.23 (s, 9H). ^{13}C NMR (125MHz, CDCl_3) δ 167.6, 166.4, 151.8, 146.0, 130.5, 128.7, 117.2, 64.8, 64.4, 29.5, 29.4, 29.3, 29.2, 28.8, 28.7, 26.0 (2C), 18.4, 0.5 (3C). HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{36}\text{O}_4\text{Si}$ $[\text{M}+\text{H}]^+$ 381.2461; found 381.2460. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2945, 2860, 1769, 1720, 1658, 1629, 1432, 1370, 1259, 1120, 920, 850.



Compound 3af Following general procedure, **3af** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (50 mg, 0.146 mmol, 73%). ^1H NMR (400 MHz, CDCl_3) δ 7.38 (d, $J = 15.9$ Hz, 1H), 6.51 (q, $J = 7.2$ Hz, 1H), 5.79 (d, $J = 15.7$ Hz, 1H), 4.09 (t, $J = 6.4$ Hz, 2H), 4.03 (t, $J = 6.4$ Hz, 2H), 2.03 (s, 3H), 1.89 (d, $J = 7.2$ Hz, 3H), 1.65 - 1.59 (m, 6H), 1.34 (m, 4H), 0.22 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ



171.3, 167.5, 151.8, 146.0, 138.4, 117.2, 64.6, 64.2, 29.0, 28.7, 28.6, 25.9, 25.9, 21.1, 18.3, 0.5 (3C).HRMS (ESI) m/z calcd. for $C_{18}H_{32}O_4Si[M+H]^+$ 341.2148; found 341.2149. IR (neat): ν_{max}/cm^{-1} 2935, 2850, 1723, 1638, 1463, 1415, 1370, 1293, 1125, 935. 860

Compound 3ba Following general procedure, **3ba** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (45 mg, 0.166 mmol, 83%).¹H NMR (500 MHz, CDCl₃) δ7.37 (d, $J = 16.0$ Hz, 1H), 7.19 (t, $J = 7.4$ Hz, 2H), 7.07 (t, $J = 7.2$ Hz, 1H), 6.98 (d, $J = 6.9$ Hz, 2H), 6.57 (q, $J = 7.2$ Hz, 1H), 5.76 (d, $J = 16.0$ Hz, 1H), 3.73 (s, 3H), 2.26 (s, 2H), 1.76 (d, $J = 6.9$ Hz, 3H), 0.20 (s, 6H).¹³C NMR (100MHz, CDCl₃) δ167.8, 152.0, 147.0, 139.3, 136.7, 128.3 (2C), 128.2 (2C), 124.4, 117.0, 51.5, 26.1, 18.4, -1.3 (2C).HRMS (ESI) m/z calcd. for $C_{16}H_{22}O_2Si [M+H]^+$ 275.1467; found 275.1469. IR (neat): ν_{max}/cm^{-1} 3033, 2940, 1820, 1765, 1730, 1663, 1615, 1450, 1370, 1260, 1123, 960, 835.

Compound 3bb Following general procedure, **3bb** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (54 mg, 0.17 mmol, 85%).¹H NMR (500 MHz, CDCl₃) δ7.35 (d, $J = 15.5$ Hz, 1H), 7.18 (t, $J = 7.4$ Hz, 2H), 7.06 (t, $J = 7.2$ Hz, 1H), 6.98 (d, $J = 7.4$ Hz, 2H), 6.59 (q, $J = 6.9$ Hz, 1H), 5.75 (d, $J = 16.0$ Hz, 1H), 4.12 (t, $J = 6.4$ Hz, 2H), 2.26 (s, 2H), 1.76 (d, $J = 6.9$ Hz, 3H), 1.65 (m, 2H), 1.40 (m, 2H), 0.93 (t, $J = 7.2$ Hz, 3H), 0.20 (s, 6H).¹³C NMR (125MHz, CDCl₃) δ167.4, 151.5, 146.5, 139.3, 136.8, 128.3 (2C), 128.2 (2C), 124.4, 117.6, 64.1, 30.9, 26.1, 19.3, 18.3, 13.8, -1.3 (2C).HRMS (ESI) m/z calcd. for $C_{19}H_{28}O_2Si [M+H]^+$ 317.1937; found 317.1938. IR (neat): ν_{max}/cm^{-1} 3025, 2930, 1835, 1740, 1715, 1670, 1630, 1425, 1360, 1225, 1115, 930, 840.

Compound 3bc Following general procedure, **3bc** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (54 mg, 0.164 mmol, 82%).¹H NMR (500 MHz, CDCl₃) δ7.36 (d, $J = 16.0$ Hz, 1H), 7.16 (t, $J = 7.4$ Hz, 2H), 7.09 (t, $J = 7.2$ Hz, 1H), 6.98 (d, $J = 7.4$ Hz, 2H), 6.59 (q, $J = 7.1$ Hz, 1H), 5.75 (d, $J = 16.0$ Hz, 1H), 3.91 (d, $J = 6.9$ Hz, 2H), 2.26 (s, 2H), 1.96 (m, 1H), 1.77 (d, $J = 6.9$ Hz, 3H), 0.95 (d, $J = 6.9$ Hz, 6H), 0.20 (s, 6H).¹³C NMR (125MHz, CDCl₃) δ167.4, 151.5, 146.3, 139.3, 136.8, 128.3 (2C), 128.2 (2C), 124.4, 117.6, 70.4, 27.9, 26.1, 19.2 (2C), 18.4, -1.3 (2C).HRMS (ESI) m/z calcd. for $C_{19}H_{28}O_2Si [M+H]^+$ 317.1937; found 317.1938. IR (neat): ν_{max}/cm^{-1} 3026, 2932, 1839, 1742, 1717, 1672, 1632, 1430, 1365, 1229, 1116, 938, 838.

Compound 3cb Following general procedure, **3cb** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (45 mg, 0.16 mmol, 80%).¹H NMR (500 MHz, CDCl₃) δ7.43 (d, $J = 15.9$ Hz, 1H), 6.59 (q, $J = 6.9$ Hz, 1H), 5.79 (d, $J = 15.4$ Hz, 1H), 4.12 (t, $J = 6.7$ Hz, 2H), 1.88 (d, $J = 7.2$ Hz, 3H), 1.67 - 1.62 (m, 2H), 1.42 - 1.37 (m, 2H), 0.92 (t, $J = 6.7$ Hz, 3H), 0.91 (s, 9H), 0.20 (s, 6H).¹³C NMR (125MHz, CDCl₃) δ167.5, 152.8, 145.1, 136.8, 117.3, 64.1, 30.9, 27.0 (3C), 19.3, 19.1, 18.5, 13.8, -3.2 (2C).HRMS (ESI) m/z calcd. for $C_{16}H_{30}O_2Si [M+H]^+$ 283.2093; found 283.2097. IR (neat): ν_{max}/cm^{-1} 2965, 2939, 2872, 1773, 1720, 1643, 1630, 1315, 1173, 1050, 960, 855.


Compound 3ag Following general procedure, **3ag** was obtained as a pale yellow solid (15:1::pet ether:EtOAc) (43 mg, 0.154 mmol, 78%).¹H NMR (500 MHz, CDCl₃) δ7.87 (d, $J = 7.4$ Hz, 2H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.51 (t, $J = 7.4$ Hz, 2H), 7.37 (d, $J = 14.9$ Hz, 1H), 6.60 - 6.54 (m, 1H), 6.24 (d, $J = 14.9$ Hz, 1H), 1.89 (d, $J = 7.4$ Hz, 3H), 0.19 (s, 9H).¹³C NMR (125MHz, CDCl₃) δ149.6, 147.6, 141.5, 136.7, 133.1, 129.3 (2C), 127.5 (2C), 125.9, 18.5, 0.3(3C).HRMS (ESI) m/z calcd. for $C_{14}H_{20}O_2SSi [M+H]^+$ 281.1032; found 281.1035. IR (neat): ν_{max}/cm^{-1} 3039, 2945, 1820, 1778, 1715, 1660, 1615, 1472, 1343, 1235, 1132, 1055, 960, 853.

Compound 3bg Following general procedure, **3bg** was obtained as a pale yellow solid (15:1::pet ether:EtOAc) (54 mg, 0.152 mmol, 76%).¹H NMR (500 MHz, CDCl₃) δ7.82 (d, $J = 7.4$ Hz, 2H), 7.59 (t, $J = 7.2$ Hz, 1H), 7.52 (t, $J = 7.4$ Hz, 2H), 7.30 (d, $J = 15.5$ Hz, 1H), 7.10 (t, $J = 7.4$ Hz, 2H), 6.99 (t, $J = 7.4$ Hz, 1H), 6.90 (d, $J = 6.9$ Hz, 2H), 6.58 (q, $J = 7.4$ Hz, 1H), 6.05 (d, $J = 14.9$ Hz, 1H), 2.21 (s, 2H), 1.80 (d, $J = 7.4$ Hz, 3H), 0.18 (s, 6H).¹³C NMR (125 MHz, CDCl₃) δ149.3, 148.0, 141.3, 138.8, 135.3, 133.1, 129.3 (2C), 128.3, 128.2 (3C), 127.5(2C), 126.3, 124.5, 25.9, 18.5, -1.5 (2C).HRMS (ESI) m/z calcd. for $C_{20}H_{24}O_2SSi [M+H]^+$ 357.1345; found 357.1349. IR (neat): ν_{max}/cm^{-1} 3050, 2958, 2936, 2915, 1816, 1780, 1740, 1615, 1602, 1520, 1459, 1368, 1232, 1128, 1059, 960, 856.


Compound 3da Following general procedure, **3da** was obtained as a pale yellow oil (30:1::pet ether:EtOAc) (49 mg, 0.136 mmol, 68%).¹H NMR (500 MHz, CDCl₃) δ7.55 (d, $J = 8.0$ Hz, 4H), 7.42 - 7.38 (m, 2H), 7.37 - 7.33 (m, 4H), 7.10 (dd, $J = 10.9, 15.5$ Hz, 1H), 6.18 - 6.08 (m, 1H), 5.95 (dd, $J = 10.9, 14.9$ Hz, 1H), 5.59 (d, $J = 14.9$ Hz, 1H), 3.68 (s, 3H), 2.30 (d, $J = 8.0$ Hz, 2H), 1.07 (s, 9H).¹³C NMR

(125MHz, CDCl₃) δ 168.0, 145.6, 141.9, 136.0 (4C), 133.7, 129.5 (2C), 128.5, 127.8 (5C), 117.1, 51.4, 27.9 (3C), 19.4, 18.7. HRMS (ESI) m/z calcd. for C₂₃H₂₈O₂Si [M+H]⁺ 365.1937; found 365.1938. IR (neat): v_{max}/cm⁻¹ 3080, 3032, 2980, 2936, 2915, 1826, 1790, 1745, 1630, 1580, 1523, 1480, 1353, 1238, 1130, 1030, 953, 842.


Compound 5aa Following general procedure, **5aa** was obtained as a white solid (8.5:1.5::pet ether:EtOAc) (54 mg, 0.132 mmol, 66%). ¹H NMR (500 MHz, CDCl₃) δ 7.18 (d, J = 15.6 Hz, 1 H), 5.83 (q, J = 7.2 Hz, 1 H), 5.75 (d, J = 15.6 Hz, 1 H), 3.75 (s, 3 H), 2.54 (t, J = 7.6 Hz, 2 H), 1.77 - 1.72 (m, 2 H), 1.69 (d, J = 7.2 Hz, 3 H), 1.42 - 1.38 (m, 2 H), 1.27 (s, 26 H), 0.88 (t, J = 6.7 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 170.9, 167.3, 145.7, 139.7, 126.3, 116.7, 52.0, 34.2, 32.3, 30.0(8C), 29.9, 29.8, 29.7, 29.5, 25.4, 23.0, 14.5, 12.6. HRMS (ESI) m/z calcd. for C₂₅H₄₄O₄ [M+NH₄]⁺ 426.3583; found 426.3583. IR (neat): v_{max}/cm⁻¹ 2925, 2854, 1764, 1725, 1652, 1628, 1435, 1306, 1167.




Compound 5ba Following general procedure, **5ba** was obtained as a pale yellow oil (8:2::pet ether:EtOAc) (28 mg, 0.13mmol, 65%). ¹H NMR (500 MHz, CDCl₃): δ 7.19 (d, J = 15.5 Hz, 1 H), 5.85 - 5.80 (m, 1 H), 5.73 (d, J = 15.5 Hz, 1 H), 3.75 (s, 3 H), 2.81 (spt, J = 7.0 Hz, 1 H), 1.68 (d, J = 7.2 Hz, 3 H), 1.33 (s, 3 H), 1.32 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 174.2, 167.3, 145.6, 139.7, 126.2, 116.5, 77.1, 52.0, 34.3, 19.5(2C), 12.4. HRMS (ESI) m/z calcd. for C₁₁H₁₆O₄ [M+H]⁺ 213.1127; found 213.1134. IR (neat): v_{max}/cm⁻¹ 2975, 2950, 1757, 1721, 1652, 1627, 1436, 1306, 1168.




Compound 5ca Following general procedure, **5ca** was obtained as a white solid (8:2::pet ether:EtOAc) (35 mg, 0.136 mmol, 68%). ¹H NMR (400 MHz, CDCl₃): δ 7.17 (d, J = 15.3 Hz, 1 H), 5.82 (q, J = 7.3 Hz, 1 H), 5.74 (d, J = 15.9 Hz, 1 H), 3.74 (s, 3 H), 2.54 (t, J = 7.3 Hz, 2 H), 1.77 - 1.72 (m, 2 H), 1.68 (d, J = 7.2 Hz, 3 H), 1.43 - 1.37 (m, 2 H), 1.35 - 1.31 (m, 4 H), 0.89 (t, J = 6.7 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ 170.9, 167.3, 145.6, 139.7, 126.3, 116.6, 52.0, 34.2, 31.7, 29.2, 25.3, 22.8, 14.3, 12.6. HRMS (ESI) m/z calcd. for C₁₄H₂₃O₄ [M+H]⁺ 255.1596; found 255.1591. IR (neat): v_{max}/cm⁻¹ 2931, 2859, 1761, 1723, 1652, 1628, 1435, 1308, 1168.




Compound 5da Following general procedure, **5da** was obtained as a pale yellow oil (8:2::pet ether:EtOAc) (32 mg, 0.142mmol, 71%). ¹H NMR (500 MHz, CDCl₃): δ 7.17 (d, J = 15.5 Hz, 1 H), 5.83 (q, J = 7.3 Hz, 1 H), 5.74 (d, J = 15.5 Hz, 1 H), 3.74 (s, 3 H), 2.42 (d, J = 7.2 Hz, 2 H), 2.27 - 2.18 (m, 1 H), 1.69 (d, J = 7.2 Hz, 3 H), 1.05 (s, 3 H), 1.04 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 169.9, 167.1, 145.4, 139.5, 126.0, 116.4, 51.8, 42.8, 25.7, 22.5(2C), 12.4. HRMS (ESI) m/z calcd. for C₁₂H₁₈O₄ [M+H]⁺ 227.1283; found 227.1280. IR (neat): v_{max}/cm⁻¹ 2959, 2874, 1760, 1723, 1653, 1628, 1466, 1307, 1169.




Compound 5ea Following general procedure, **5ea** was obtained as a white solid (8:2::pet ether:EtOAc) (25mg, 0.086mmol, 43%). ¹H NMR (400 MHz, CDCl₃): δ 7.27 (d, J = 15.9 Hz, 1 H), 6.94 (s, 2 H), 5.98 - 5.88 (m, 2 H), 3.75 (s, 3 H), 2.47 (s, 6 H), 2.33 (s, 3 H), 1.85 (d, J = 6.7 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 167.4, 166.8, 145.9, 140.7, 140.1, 136.9(2C), 129.5(2C), 129.1, 126.6, 117.0, 52.1, 21.5, 21.4(2C), 13.3. HRMS (ESI) m/z calcd. for C₁₇H₂₄NO₄ [M+NH₄]⁺ 306.1705; found 306.1705. IR (neat): v_{max}/cm⁻¹ 2923, 2852, 1725, 1612, 1651, 1435, 1307, 1234, 1165, 1052.



Compound 5fa Following general procedure, **5fa** was obtained as a white solid (8:2::pet ether:EtOAc) (29 mg, 0.096 mmol, 48%). ¹H NMR (400 MHz, CDCl₃): δ 7.18 (d, J = 15.9 Hz, 1 H), 5.81 (q, J = 7.3 Hz, 1 H), 5.70 (d, J = 15.9 Hz, 1 H), 3.75 (s, 3 H), 2.09 (br. s., 3 H), 2.07 (br. s., 6 H), 1.77 (br. s., 6 H), 1.66 (d, J = 6.7 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 174.7, 167.4, 145.6, 139.9, 126.2, 116.4, 52.0, 41.6, 39.3(3C), 36.7(3C), 28.2(3C), 12. HRMS (ESI) m/z calcd. for C₁₈H₂₄O₄ [M+NH₄]⁺ 322.2018; found 322.2019. IR (neat): v_{max}/cm⁻¹ 2909, 2853, 1750, 1722, 1651, 1627, 1453, 1435, 1307, 1201, 1180, 1167.



Compound 5ga Following general procedure, **5ga** was obtained as a pale yellow oil (8:2::pet ether:EtOAc) (24 mg, 0.13 mmol, 65%). ¹H NMR (500 MHz, CDCl₃): δ 7.17 (d, J = 15.6 Hz, 1 H), 5.82 (q, J = 7.2 Hz, 1 H), 5.77 (d, J = 15.5 Hz, 1 H), 3.75 (s, 3 H), 2.28 (s, 3 H), 1.70 (d, J = 7.2 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 167.8, 167.0, 145.4, 139.2, 126.1, 116.5, 51.8, 20.4, 12.3. HRMS (ESI) m/z calcd. for C₉H₁₂O₄ [M+H]⁺ 185.0814; found 185.0818. IR (neat): v_{max}/cm⁻¹ 3058, 2953, 1762, 1723, 1653, 1628, 1436, 1310, 1200, 1171.



NOESY shows that H_a (5.80 - 5.86) and H_b (7.19 - 7.15) are correlated. H_c (5.76 - 5.78) and H_d (1.70) are weakly correlated.

Compound 5gb Following general procedure, **5gb** was obtained as a pale yellow oil (8:2::pet ether:EtOAc) (32 mg, 0.140 mmol, 70%). ¹H NMR (500 MHz, CDCl₃): δ 7.15 (d, *J* = 15.5 Hz, 1 H), 5.82 (q, *J* = 7.3 Hz, 1 H), 5.76 (d, *J* = 15.5 Hz, 1 H), 4.15 (t, *J* = 7.1 Hz, 3 H), 2.28 (s, 3 H), 1.69 (d, *J* = 7.3 Hz, 3 H), 1.66 - 1.63 (m, 2 H), 1.42 - 1.38 (m, 2 H), 0.94 (t, *J* = 7.1 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 168.1, 166.9, 145.8, 139.1, 126.0, 117.3, 64.8, 31.1, 20.6, 19.5, 14.0, 12.5. HRMS (ESI) m/z calcd. for C₁₂H₁₈O₄ [M+H]⁺ 227.1283; found 227.1281. IR (neat): ν_{max}/cm⁻¹ 2960, 2934, 2874, 1765, 1715, 1653, 1627, 1304, 1196, 1170.

Compound 5gc Following general procedure, **5gc** was obtained as a pale yellow oil (8:2::pet ether:EtOAc) (31 mg, 0.136 mmol, 68%). ¹H NMR (500 MHz, CDCl₃): δ 7.16 (d, *J* = 15.5 Hz, 1 H), 5.83 (q, *J* = 7.3 Hz, 1 H), 5.77 (d, *J* = 15.6 Hz, 1 H), 3.93 (d, *J* = 6.6 Hz, 2 H), 2.29 (s, 3 H), 2.00 - 1.92 (m, 1 H), 1.70 (d, *J* = 7.2 Hz, 3 H), 0.95 (d, *J* = 6.7 Hz, 6 H). ¹³C NMR (125 MHz, CDCl₃): δ 167.8, 166.6, 145.4, 138.8, 125.8, 116.9, 70.7, 27.8, 20.4, 19.1(2C), 12.2. HRMS (ESI) m/z calcd. for C₁₂H₁₈O₄ [M+H]⁺ 227.1283; found 227.1282. IR (neat): ν_{max}/cm⁻¹ 2962, 2928, 2875, 2854, 1765, 1718, 1627, 1653, 1470, 1371, 1211, 1197, 1168.

Compound 5gd Following general procedure, **5gd** was obtained as a white solid (8:2::pet ether:EtOAc) (32 mg, 0.128 mmol, 64%). ¹H NMR (500 MHz, CDCl₃): δ 7.15 (d, *J* = 15.6 Hz, 1 H), 5.82 (q, *J* = 7.3 Hz, 1 H), 5.74 (d, *J* = 15.5 Hz, 1 H), 4.85 - 4.78 (m, 1 H), 2.28 (s, 3 H), 1.89 - 1.84 (m, 2 H), 1.74 (m, 2 H), 1.69 (d, *J* = 7.3 Hz, 3 H), 1.58 - 1.52 (m, 1 H), 1.44 - 1.36 (m, 4 H), 1.29 - 1.24 (m, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ 167.8, 166.0, 145.5, 138.5, 125.6, 117.5, 72.9, 31.7(2C), 25.4, 23.8(2C), 20.4, 12.2. HRMS (ESI) m/z calcd. for C₁₄H₂₀O₄ [M+H]⁺ 253.1440; found 253.1443. IR (neat): ν_{max}/cm⁻¹ 2936, 2859, 1764, 1713, 1653, 1626, 1450, 1371, 1259, 1197, 1173.

Compound 5gh Following general procedure, **5gh** was obtained as a pale yellow oil (8:2::pet ether:EtOAc) (29 mg, 0.144 mmol, 72%). ¹H NMR (500 MHz, CDCl₃): δ 7.16 (d, *J* = 15.5 Hz, 1 H), 5.85 - 5.80 (m, 1 H), 5.75 (d, *J* = 15.6 Hz, 1 H), 4.20 (q, *J* = 7.2 Hz, 2 H), 2.28 (s, 3 H), 1.70 (d, *J* = 7.2 Hz, 3 H), 1.29 (t, *J* = 7.1 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 168.1, 166.8, 145.7, 139.2, 126.1, 117.2, 60.9, 20.7, 14.6, 12.5. HRMS (ESI) m/z calcd. for C₁₀H₁₄O₄ [M+NH₄]⁺ 216.1236; found 216.1233. IR (neat): ν_{max}/cm⁻¹ 2982, 1764, 1714, 1652, 1628, 1369, 1305, 1197, 1175.

Compound 5gi Following general procedure, **5gi** was obtained as a white solid (8:2::pet ether:EtOAc) (40 mg, 0.148 mmol, 74%). ¹H NMR (500 MHz, CDCl₃): δ 7.16 (d, *J* = 15.5 Hz, 1 H), 5.83 (q, *J* = 7.3 Hz, 1 H), 5.76 (d, *J* = 15.6 Hz, 1 H), 4.14 (t, *J* = 6.8 Hz, 2 H), 2.29 (s, 3 H), 1.70 (d, *J* = 7.3 Hz, 3 H), 1.67 - 1.64 (m, 2 H), 1.32 (m, 8 H), 0.89 (t, *J* = 7.0 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ 168.1, 167.0, 145.7, 139.1, 126.1, 117.2, 65.1, 32.1, 29.3, 29.0, 26.2, 22.9, 20.7, 14.4, 12.5. HRMS (ESI) m/z calcd. for C₁₅H₂₄O₄ [M+H]⁺ 269.1753; found 269.1757. IR (neat): ν_{max}/cm⁻¹ 2925, 2855, 1727, 1651, 1627, 1453, 1435, 1307, 1261, 1180, 1167.

Compound 5ge Following general procedure, **5ge** was obtained as a white solid (8:2::pet ether:EtOAc) (40 mg, 0.108 mmol, 54%). ¹H NMR (400 MHz, CDCl₃): δ 87.16 (d, *J* = 15.5 Hz, 1 H), 6.40 (dd, *J* = 1.4, 17.3 Hz, 1 H), 6.12 (dd, *J* = 10.5, 17.3 Hz, 1 H), 5.84 - 5.80 (m, 2 H), 5.75 (d, *J* = 15.5 Hz, 1 H), 4.17 - 4.12 (m, 4 H), 2.28 (s, 3 H), 1.70 (d, *J* = 7.3 Hz, 3 H), 1.68 - 1.63 (m, 4 H), 1.37 - 1.31 (m, 10 H). ¹³C NMR (100 MHz, CDCl₃): δ 167.8, 166.6, 166.4, 145.4, 138.8, 130.5, 128.7, 125.8, 116.9, 64.7, 64.7, 29.4, 29.2(2C), 28.7, 28.6, 25.9(2C), 20.4, 12.2. HRMS (ESI) m/z calcd. for C₂₀H₃₀O₆ [M+H]⁺ 367.2121; found 367.2121. IR (neat): ν_{max}/cm⁻¹ 2930, 2856, 1725 (br), 1636, 1465, 1408, 1371, 1370, 1302, 1288, 1297, 1272, 1196.

Compound 5gj Following general procedure, **5gj** was obtained as a white solid (8:2::pet ether:EtOAc) (48 mg, 0.156 mmol, 78%). ¹H NMR (400 MHz, CDCl₃): δ 7.15 (d, *J* = 15.3 Hz, 1 H), 5.84 (q, *J* = 7.3 Hz, 1 H), 5.78 (d, *J* = 15.9 Hz, 1 H), 4.97 - 4.92 (m, 1 H), 2.42 - 2.34 (m, 1 H), 2.31 (s, 3 H), 2.01 - 1.93 (m, 1 H), 1.77 (ddd, *J* = 4.0, 7.6, 11.6 Hz, 1 H), 1.70 (d, *J* = 7.3 Hz, 3 H), 1.37 - 1.22 (m, 3 H), 1.01 (dd, *J* = 3.4, 13.7 Hz, 1 H), 0.92 (s, 3 H), 0.88 (s, 3 H), 0.85 (s, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ 167.9, 166.9, 145.4, 138.5, 125.7, 117.4, 80.2, 48.9, 47.9, 44.9, 36.8, 28.0, 27.2, 20.4, 19.7, 18.9, 13.5, 12.2. HRMS (ESI) m/z calcd. for C₁₈H₂₆O₄ [M+NH₄]⁺ 324.2175; found 324.2177. IR (neat): ν_{max}/cm⁻¹ 2924, 2864, 1750, 1722, 1651, 1627, 1453, 1435, 1307, 1201, 1180, 1167. [α]_D³⁰ = -20.68 (c = 0.81 in CHCl₃).

Compound 5gk Following general procedure, **5gk** was obtained as a white solid (8:2::pet ether:EtOAc) (42 mg, 0.160 mmol, 80%). ¹H NMR (400 MHz, CDCl₃): δ 7.16 (d, *J* = 15.9 Hz, 1 H), 5.83 (q, *J* = 7.1 Hz, 1 H), 5.76 (d, *J* = 15.3 Hz, 1 H), 3.96 (d, *J* = 6.7 Hz, 2 H), 2.29 (s, 3 H), 1.76 - 1.66 (m, 10 H), 1.28 - 1.21 (m, 3 H), 1.02 - 0.98 (m, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ 168.1, 167.0, 145.8, 139.1, 126.0, 117.3, 70.1, 37.5, 30.1(2C), 26.7, 26.0(2C), 20.7, 12.5. HRMS (ESI) m/z calcd. for C₁₅H₂₂O₄ [M+Na]⁺ 289.1416; found 289.1418. IR (neat): ν_{max}/cm⁻¹ 2928, 2854, 1766, 1715, 1651, 1627, 1450, 1370, 1305, 1288, 1196, 1168, 1023.

Compound 5gl Following general procedure, **5gl** was obtained as a white solid (8:2::pet ether:EtOAc) (43 mg, 0.14 mmol, 70%). ¹H NMR (400 MHz, CDCl₃): δ 7.14 (d, *J* = 15.9 Hz, 1 H), 5.82 (q, *J* = 7.1 Hz, 1 H), 5.75 (d, *J* = 15.3 Hz, 1 H), 4.76 (dt, *J* = 4.3, 10.7 Hz, 1 H), 2.29 (s, 3 H), 2.04 - 1.98 (m, 1 H), 1.91 - 1.84 (m, 1 H), 1.69 [m, 4 H (3H + 1H)], 1.55 - 1.45 (m, 1 H), 1.43 - 1.36 (m, 1 H), 1.10 - 0.97 (m, 2 H), 0.92 - 0.88 (m, 8 H), 0.75 (d, *J* = 6.7 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ 168.2, 166.4, 145.8, 138.9, 126.0, 117.6, 74.6, 47.5, 41.3, 34.6, 31.7, 26.5, 23.7, 22.4, 21.1, 20.7, 16.6, 12.5. HRMS (ESI) m/z calcd. for C₁₈H₂₈O₄ [M+Na]⁺ 331.1885; found 331.1889. IR (neat): ν_{max}/cm⁻¹ 2956, 2929, 2870, 1766, 1711, 1651, 1626, 1455, 1370, 1302, 1288, 1196, 1171. [α]_D³⁰ = -15.78 (c = 0.58 in CHCl₃).

Compound 5gm Following general procedure, **5gm** was obtained as a brownish oil (8:2::pet ether:EtOAc) (29 mg, 0.116 mmol, 58%). ¹H NMR (500 MHz, CDCl₃): δ 7.41 - 7.38 (m, 2 H), 7.36 (d, *J* = 15.5 Hz, 1 H), 7.26 - 7.22 (m, 1 H), 7.12 (d, *J* = 7.6 Hz, 2 H), 5.98 - 5.90 (m, 2 H), 2.33 (s, 3 H), 1.75 (d, *J* = 7.2 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 168.1, 165.3, 151.1, 145.8, 141.0, 129.8(2C), 127.4, 126.2, 121.9(2C), 116.4, 20.7, 12.7. HRMS (ESI) m/z calcd. for C₁₄H₁₄O₄ [M+H]⁺ 247.0970; found 247.0973. IR (neat): ν_{max}/cm⁻¹ 2924, 2854, 1762, 1731, 1649, 1626, 1493, 1371, 1290, 1192, 1141.

Compound 5gn Following general procedure, **5gn** was obtained as a white solid (8:2::pet ether:EtOAc) (36 mg, 0.138 mmol, 69%). ¹H NMR (500 MHz, CDCl₃): δ 7.39 - 7.35 (m, 5 H), 7.21 (d, *J* = 15.5 Hz, 1 H), 5.86 - 5.80 (m, 2 H), 5.20 (s, 2 H), 2.27 (s, 3 H), 1.70 (d, *J* = 7.2 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 167.7, 166.4, 145.5, 139.5, 136.0, 128.7(2C), 128.4(2C), 128.4, 126.2, 116.6, 66.5, 20.4, 12.3. HRMS (ESI) m/z calcd. for C₁₅H₁₆O₄ [M+NH₄]⁺ 278.1392; found 278.1394. IR (neat): ν_{max}/cm⁻¹ 3034, 2938, 1815, 1760, 1723, 1650, 1626, 1455, 1372, 1264, 1198, 1165.

Compound 5ag Following general procedure, **5ag** was obtained as a white solid (8:2::pet ether:EtOAc) (43 mg, 0.088 mmol, 44%). ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, *J* = 7.3 Hz, 2 H), 7.62 (t, *J* = 7.3 Hz, 1 H), 7.53 (t, *J* = 7.6 Hz, 2 H), 7.19 (d, *J* = 14.6 Hz, 1 H), 6.20 (d, *J* = 14.6 Hz, 1 H), 5.95 (q, *J* = 7.3 Hz, 1 H), 2.47 (t, *J* = 7.6 Hz, 2 H), 1.69 (d, *J* = 7.1 Hz, 3 H), 1.68 - 1.63 (m, 2 H), 1.31 - 1.25 (m, 28 H), 0.88 (t, *J* = 6.7 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ 170.2, 143.6, 140.5, 137.8, 133.4, 129.3(2C), 128.8, 127.6(2C), 125.7, 33.8, 31.9, 29.7(6C), 29.6, 29.6, 29.4, 29.4, 29.2, 29.1, 24.9, 22.7, 14.2, 12.6. HRMS (ESI) m/z calcd. for C₂₉H₄₆O₄S [M+NH₄]⁺ 508.3461; found 508.3463. IR (neat): ν_{max}/cm⁻¹ 2923, 2853, 1763, 1652, 1601, 1447, 1308, 1192, 1147, 1112, 1085.

Compound 5cg Following general procedure, **5cg** was obtained as a white solid (8:2::pet ether:EtOAc) (34 mg, 0.10 mmol, 50%). ¹H NMR (500 MHz, CDCl₃): δ 7.88 (d, *J* = 8.2 Hz, 2 H), 7.62 (t, *J* = 7.4 Hz, 1 H), 7.54 (t, *J* = 7.9 Hz, 2 H), 7.19 (d, *J* = 14.9 Hz, 1 H), 6.20 (d, *J* = 14.9 Hz, 1 H), 5.95 (q, *J* = 7.3 Hz, 1 H), 2.48 (t, *J* = 7.6 Hz, 2 H), 1.70 (d, *J* = 7.2 Hz, 3 H), 1.68 - 1.64 (m, 2 H), 1.34 - 1.27 (m, 6 H), 0.90 - 0.86 (m, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ 170.2, 143.6, 140.5, 137.8, 133.5, 129.3(2C), 128.8, 127.6 (2C), 125.7, 33.8, 31.3, 28.8, 24.9, 22.4, 14.0, 12.6. HRMS (ESI) m/z calcd. for C₁₈H₂₄O₄S [M+NH₄]⁺ 354.1739; found 354.1737. IR (neat): ν_{max}/cm⁻¹ 2923, 2853, 1721, 1650, 1661, 1447, 1308, 1147, 1084, 1025.

Compound 5gg Following general procedure, **5gg** was obtained as a white solid (8:2::pet ether:EtOAc) (28.19 mg, 0.106 mmol, 53%). ¹H NMR (500 MHz, CDCl₃): δ 7.88 (d, *J* = 8.2 Hz, 2 H), 7.62 (t, *J* = 7.4 Hz, 1 H), 7.54 (t, *J* = 7.9 Hz, 2 H), 7.19 (d, *J* = 14.9 Hz, 1 H), 6.23 (d, *J* = 14.9 Hz, 1 H), 5.96 (q, *J* = 7.2 Hz, 1 H), 2.23 (s, 3 H), 1.71 (d, *J* = 7.3 Hz, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ 167.6, 144.0, 140.8, 137.9, 133.8, 129.7(2C), 129.2, 128.0 (2C), 126.2, 20.6, 12.9. HRMS (ESI) m/z calcd. for C₁₃H₁₄O₄S [M+NH₄]⁺ 284.0957; found 284.0954. IR (neat): ν_{max}/cm⁻¹ 2923, 2852, 1762, 1652, 1600, 1447, 1371, 1306, 1194, 1145, 1085, 1023.

Procedure for Isomerization of Allylsilanes:


A 8 mL screw-cap vial was charged with $[\text{RuCl}_2(\text{p-cymene})]_2$ (6.1 mg, 0.01 mmol, 5.0 mol%), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (80 mg, 0.4 mmol, 2.0 equiv), AgSbF_6 (14 mg, 0.04 mmol, 20 mol%) and 1,2-dichloroethane (1.5 mL). Then allylsilane (0.2 mmol, 1.0 equiv) was added into the solution. The vial was sealed under N_2 and heated to 80°C with stirring for 12 h. After cooling down, the mixture was diluted with dichloromethane, filtered and concentrated to give the crude compound which was directly purified by column chromatography using only pentane as a eluent.

Compound 6b

Following general procedure, **6b** was obtained as a colourless oil (using pentane as a eluent) (34 mg, 0.174 mmol, 87%). ^1H NMR (500 MHz, CDCl_3): δ 7.21 (t, $J = 7.2$ Hz, 2 H), 7.07 (t, $J = 6.9$ Hz, 1 H), 7.00 (d, $J = 7.4$ Hz, 2 H), 6.12 - 5.99 (m, 1 H), 5.63 (d, $J = 20$ Hz, 1 H), 2.11 (s, 2 H), 1.81 (d, $J = 6.3$ Hz, 3 H), 0.02 (s, 6 H). ^{13}C NMR (125 MHz, CDCl_3): δ 143.7, 140.6, 129.8, 128.6, 128.4, 124.2, 26.5, 23.0, -3.0. HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{18}\text{Si} [\text{M}+\text{H}]^+$ 191.1256; found 191.1258. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 3078, 3022, 2988, 2953, 2849, 1799, 1618, 1599, 1492, 1247, 1055, 831, 697.


Compound 6c

Following general procedure, **6c** was obtained as a colourless oil (using pentane as a eluent) (26 mg,




Compound 6d

Following general procedure, **6d** was obtained as a colourless oil (using pentane as a eluent) (50 mg, 0.18




Compound 6e

Following general procedure, **6e** was obtained as a colourless oil (using pentane as a eluent) (34 mg, 0.17




Procedure for Deuterium study:



A 8 mL screw-cap vial was charged with $[\text{RuCl}_2(\text{p-cymene})]_2$ (11 mg, 0.017 mmol, 5.0 mol%), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (143 mg, 0.71 mmol, 2.0 equiv), AgSbF_6 (24.5 mg, 0.07 mmol, 20 mol%), 1,2-dichloroethane (2 mL) and $\text{CD}_3\text{CO}_2\text{D}$ (0.2 ml). Then Diphenyltertiarybutyl allylsilane **1d** (0.2 mmol, 1.0 equiv) was added into the solution. The vial was sealed under N_2 and heated to 80°C with stirring for 5 h. After cooling down, the mixture was diluted with dichloromethane, filtered and concentrated to give the crude compound which was directly purified by column chromatography using only pentane as a eluent to afford compound **6d**. It was found that deuterium scrambling at the α -position ($> 20\%$) as well as at the methyl group ($> 45\%$) in vinylsilane.

Coupling reaction between vinylsilane **6b** and methyl acrylate **2a**:




A 8 mL screw-cap vial was charged with $[\text{RuCl}_2(\text{p-cymene})]_2$ (11 mg, 0.017 mmol, 5.0 mol%), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (143 mg, 0.71 mmol, 2.0 equiv), AgSbF_6 (24.5 mg, 0.07 mmol, 20 mol%) and 1,2-dichloroethane (2 mL). Then vinylsilane **6b** (70 mg,

0.4 mmol, 1.2 equiv) and methyl acrylate **2a** (30 mg, 0.35 mmol, 1.0 equiv) were added into the solution. The vial was sealed under N₂ and heated to 80°C with stirring for 16 h. After cooling down, the mixture was diluted with dichloromethane, filtered and concentrated to give the crude compound which was directly purified by column chromatography using 30:1 pet:ether:EtOAc as a eluent to afford compound **3b'a** (77 mg, 0.28 mmol, 80%).

¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 15.9 Hz, 1 H), 7.18 (t, *J* = 7.6 Hz, 2 H), 7.06 (t, *J* = 7.3 Hz, 1 H), 6.96 (d, *J* = 6.7 Hz, 2 H), 6.68 - 6.47 (m, 1 H), 5.75 (d, *J* = 15.9 Hz, 1 H), 3.72 (s, 3 H), 2.25 (s, 2 H), 1.75 (d, *J* = 7.3 Hz, 3 H), 0.19 (s, 6 H). ¹³C NMR (125 MHz, CDCl₃) δ 167.8, 151.9, 146.8, 139.3, 136.8, 128.3, 128.3, 124.4, 117.1, 51.5, 26.1, 18.4, -1.3.

Procedure for Diels-Alder reaction:




Compound **3aa** (100 mg, 0.5 mmol, 1.0 equiv.,) and N-phenyl maleimide **7** (88 mg, 0.5 mmol, 1.0 equiv.,) were taken in 8 mL screw-cap vial and Toluene (1.5 ml) was added. Then reaction mixture was heated at 80 °C for 15 h. After cooling down, Toluene was removed under reduced pressure and crude compound was directly purified by column chromatography using 0 - 20% EtOAc in Pet ether as a eluent to afford single diastereomer **8** (130 mg, 0.35 mmol) in 70% yield.

Compound 8:

¹H NMR (500 MHz, CDCl₃): δ 7.44 - 7.38 (m, 2 H), 7.36 - 7.31 (m, 1 H), 7.19 - 7.13 (m, 2 H), 6.67 (dd, *J* = 2.6, 3.7 Hz, 1 H), 3.80 (s, 3 H), 3.77 - 3.69 (m, 1 H), 3.33 - 3.25 (m, 1 H), 3.23 - 3.15 (m, 1 H), 2.67 (t, *J* = 6.9 Hz, 1 H), 1.56 (d, *J* = 7.4 Hz, 3 H), 0.13 (s, 9 H). ¹³C NMR (125 MHz, CDCl₃): δ 176.5, 176.4, 171.4, 148.0, 135.3, 131.8, 129.1, 128.6, 126.5, 52.4, 44.6, 42.9, 41.1, 35.6, 16.7, -0.1. HRMS (ESI) m/z calcd. for C₂₀H₂₅NO₄Si [M+H]⁺ 372.1631; found 372.1634. IR (neat): ν_{max}/cm⁻¹ 2951, 2922, 2849, 1739, 1709, 1499, 1455, 1382, 1276, 1247, 1201, 1036, 923, 834, 690.


2.2. Gram scale synthesis and its applications

2.2a. Synthesis of compound 3gb



By following the general procedure, A 100 mL seal tube was charged with [RuCl₂(p-cymene)]₂ (307 mg, 0.5 mmol, 5.0 mol%), Cu(OAc)₂·H₂O (4.0 g, 20 mmol, 2.0 equiv), AgSbF₆ (685 mg, 2.0 mmol, 20 mol%) and 1,2-dichloroethane (30 mL). Then ethyl acrylate **2h** (1.0g, 1.06ml, 10 mmol, 1.0 equiv) and allyl acetate **4g** (1.2g, 1.3ml, 12mmol, 1.2equiv) were added into the solution in sequence. Then vial was sealed under N₂ and heated to 80 °C with stirring for 16 h. After cooling down, the mixture was diluted with ethyl acetate, filtrated and concentrated to give the crude compound which was directly purified by column chromatography (8:2 petroleum ether/ethyl acetate) to give **5gh** as a colourless oil (1.36 g, 6.9 mmol, 69%).

2.2b. Synthesis of compound 9




To a solution of **5gh** (1.3 g, 6.5 mmol, 1.0 equiv) in ethanol (15 ml), added potassium carbonate (815 mg, 5.9 mmol, 0.9 equiv) in four portions over 5 min and reaction mixture was allowed to stirred for 40 minutes at room temperature. Then reaction mixture was quenched with water and extracted with ethyl acetate (15 ml X 3), washed with brine, dried over anhydrous Na₂SO₄, concentrated *in vacuo* and purified by column chromatography (7:3 petroleum ether/ethyl acetate) furnishing the enone **9** (816 mg, 5.2 mmol, 80%) as a yellow liquid.

(E)-ethyl 4-oxohex-2-enoate (9)

¹H NMR (400 MHz, CDCl₃): δ 7.06 (d, *J* = 16.5 Hz, 1 H), 6.67 (d, *J* = 15.9 Hz, 1 H), 4.26 (q, *J* = 7.3 Hz, 2 H), 2.67 (q, *J* = 7.3 Hz, 2 H), 1.32 (t, *J* = 7.1 Hz, 3 H), 1.13 (t, *J* = 7.3 Hz, 3 H). ¹³C NMR (101 MHz, CDCl₃): δ 200.2, 165.6, 139.2, 130.6, 61.4, 34.8, 14.1, 7.6. HRMS (ESI) m/z calcd. for C₈H₁₂O₃ [M+NH₄]⁺ 174.1130; found 174.1139. IR (neat): ν_{max}/cm⁻¹ 2982, 2939, 1727, 1704, 1688, 1641, 1304, 1185.

2.2c. Synthesis of compound 13¹




To a suspension of catalyst (52 mg, 0.16 mmol, 0.1 equiv), enone **9** (250 mg, 1.60 mmol, 1 equiv) and acetic acid (10 μ l, 0.16 mmol, 0.1 equiv) in methanol (7 ml) was added heptaldehyde (0.45 ml, 365 mg, 3.2 mmol, 2 equiv) at 0 °C. The reaction mixture was stirred for 1 h at the same temperature and then warmed to room temperature for 3 h. The solution was partitioned between ethyl acetate and saturated NaHCO₃. The organic phase was separated and aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄ and concentrated. Purification of the residue by flash column chromatography (silica gel) eluting with 10:1 petroleum ether/ethyl acetate afforded the Michael adduct **13** (310 mg, 1.152 mmol, 72%) as a pale-yellow liquid.

(2*R*,3*S*)-ethyl 3-formyl-2-(2-oxobutyl)octanoate (13)

¹H NMR (400 MHz, CDCl₃): δ 9.61 (s, 1 H), 4.13 (q, *J* = 7.3 Hz, 2 H), 3.37 - 3.28 (m, 1 H), 2.97 (dd, *J* = 9.8, 17.7 Hz, 1 H), 2.65 - 2.57 (m, 1 H), 2.51 - 2.44 (m, 2 H), 2.42 - 2.36 (m, 1 H), 1.33 - 1.26 (m, 8 H), 1.23 (s, 3 H), 1.05 (t, *J* = 7.3 Hz, 3 H), 0.87 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃): δ 209.0, 202.7, 173.1, 61.1, 52.7, 40.7, 39.6, 36.1, 31.7, 27.1, 26.2, 22.4, 14.1, 13.9, 7.7. HRMS (ESI) m/z calcd. for C₁₅H₂₆O₄ [M-H]⁻ 269.1757; found 269.1753. IR (neat): ν_{max}/cm⁻¹ 2957, 2932, 2860, 1725 (br), 1461, 1376, 1212, 1179, 1115. [α]_D³⁰ = +12.68 (c = 1.6 in CHCl₃).

2.2d. Synthesis of compound 11¹




To a solution of Michael adduct **13** (100 mg, 0.37 mmol) in 4 mL of DCM, was added DBU (113 µL, 0.74 mmol, 2.0 equiv) at 0 °C. After it was stirred for 1 h at 0 °C, the solution was warmed to room temperature and stirred for 2h. The reaction mixture was partitioned between ethyl acetate and brine. The organic phase was separated and aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography (silicagel, 10:1 petroleum ether/ethyl acetate as eluent) to give the corresponding cyclohexanone.

To a solution of aldol reaction product (70 mg, 0.25 mmol) in DCM (3 mL) were added MsCl (60 μ L, 0.77 mmol, 3.0 equiv) and Et₃N (0.19 mL, 1.5 mmol, 6.0 equiv) at 0 °C. After the reaction mixture was stirred for 1 h at 0 °C, and 6 h at 25 °C, it was partitioned between ethyl acetate and brine. The organic phase was separated and aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄ and concentrated. The residual oil was purified via flash column chromatography (silica gel, 20:1 petroleum ether/ethyl acetate as eluent) to afford the corresponding cyclohexenone **11** (38 mg, 0.15 mmol, 60%).

(1S, 2S)-ethyl 4-methyl-5-oxo-2-pentylcyclohex-3-enecarboxylate (11)

¹H NMR (400 MHz, CDCl₃): δ 6.57 (br. s., 1 H), 4.15 (q, *J* = 6.9 Hz, 2 H), 2.86 - 2.75 (m, 2 H), 2.64 - 2.59 (m, 2 H), 1.77 (s, 3 H), 1.53 - 1.35 (m, 4 H), 1.30 (br. s., 4 H), 1.25 (d, *J* = 7.3 Hz, 3 H), 0.89 (t, *J* = 6.7 Hz, 3 H). ¹³C NMR (101 MHz, CDCl₃): δ 197.4, 173.8, 147.8, 135.0, 61.2, 46.1, 39.3, 38.5, 33.5, 32.1, 26.5, 22.8, 16.1, 14.5, 14.3. HRMS (ESI) m/z calcd. for C₁₅H₂₄O₃ [M+H]⁺ 253.1804; found 253.1806. IR (neat): ν_{max}/cm⁻¹ 2957, 2928, 2859, 1733, 1682, 1454, 1377, 1276, 1175, 1032. [α]_D³⁰ = +68.6 (c = 0.70 in CHCl₃).

2.2e. Synthesis of compound 12¹




The Michael adduct **13** (100 mg, 0.37 mmol) was dissolved in 3 mL THF. To this solution $\text{NaBH}(\text{OAc})_3$ (235 mg, 1.11 mmol, 3.0 equiv), AcOH (23 μl , 0.37 mmol, 1.0 equiv) and BnNH_2 (60 mg, 61 μl , 0.55 mmol, 1.5 equiv) were added at 0 °C. After it was stirred for 1 h at 0 °C, the solution was warmed to rt, and stirred for 2.5 hours. Then mixture was partitioned between ethyl acetate and saturated NaHCO_3 . The organic phase was separated and aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over Na_2SO_4 and concentrated. Purification of the residue by flash column chromatography (silica gel, 20:1 petroleum ether/ethyl acetate as eluent) afforded the corresponding piperidine **12** (82.5 mg, 0.24 mmol, 65%).

(2R,4S,5R)-ethyl 1-benzyl-2-ethyl-5-pentylpiperidine-4-carboxylate (12)

^1H NMR (400 MHz, CDCl_3): δ 7.32 - 7.28 (m, 3 H), 7.25 (br.s, 2 H), 4.17 - 4.11 (m, 2 H), 2.84 (d, J = 13.6 Hz, 1 H), 2.79 (dd, J = 2.7, 11.8 Hz, 1 H), 2.51 (td, J = 4.1, 13.1 Hz, 1 H), 2.12 - 2.07 (m, 1 H), 1.86 - 1.75 (m, 3 H), 1.73 - 1.61 (m, 4 H), 1.25 - 1.22 (m, 5 H), 1.20 - 1.15 (m, 3 H), 0.98 - 0.94 (m, 3 H), 0.92 - 0.86 (m, 3 H), 0.81 (t, J = 6.8 Hz, 3 H). ^{13}C NMR (100 MHz, CDCl_3): 8175.1, 140.7, 128.8(2C), 128.4(2C), 126.9, 62.0, 60.4, 57.5, 55.6, 46.2, 36.9, 32.3, 28.0, 27.6, 26.9, 26.3, 22.9, 14.6, 14.4, 8.6. HRMS (ESI) m/z calcd. for $\text{C}_{22}\text{H}_{35}\text{O}_2\text{N}$ [M+H]⁺ 346.2746; found 346.2735. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2957, 2929, 2873, 2856, 2791, 2754, 1732, 1453, 1377, 1338, 1254, 1237, 1185, 1169. $[\alpha]_D^{20} = -29.2$ (c = 1.1 in CHCl_3).

2.2f. Synthesis of compound 7²




To a solution of thiophenol (39 mg, 36 μl , 0.35 mmol, 1.1 equiv) and Quinine (10.5 mg, 0.032 mmol, 0.1 equiv) in toluene, was added enone **9** (50 mg, 0.32 mmol, 1 equiv) at rt and reaction mixture was allowed stirred for 6 h. Then reaction mixture was quenched with water and extracted with ethyl acetate (15ml X 3), washed with brine, dried over anhydrous Na_2SO_4 , concentrated *in vacuo* and purified by column chromatography furnishing the product **10**² (61.2 mg, 0.23 mmol, 72%).

Ethyl 4-oxo-2-(phenylthio)hexanoate (10)

^1H NMR (400 MHz, CDCl_3): δ 7.54 - 7.45 (m, 2 H), 7.37 - 7.29 (m, 3 H), 4.11 (q, J = 7.1 Hz, 2 H), 4.06 (dd, J = 4.6, 10.1 Hz, 1 H), 3.10 (dd, J = 10.4, 17.7 Hz, 1 H), 2.79 (dd, J = 4.6, 18.0 Hz, 1 H), 2.48 - 2.39 (m, 2 H), 1.17 (t, J = 7.3 Hz, 3 H), 1.05 (t, J = 7.3 Hz, 3 H). ^{13}C NMR (100 MHz, CDCl_3): δ 208.4, 171.9, 134.0 (2C), 132.7, 129.3 (2C), 128.8, 61.7, 45.1, 44.3, 36.3, 14.3, 7.9. HRMS (ESI) m/z calcd. for $\text{C}_{14}\text{H}_{18}\text{O}_3\text{S}$ [M+Na]⁺ 289.0874; found 289.0878. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2979, 2938, 2906, 1731, 1582, 1439, 1369, 1223, 1173, 1153.

2.3. Synthesis of norpyrenophorin (14)

2.3a. Synthesis of compound 19




By following the general procedure, A 50 mL seal tube was charged with $[\text{RuCl}_2(\text{p-cymene})]_2$ (179 mg, 5.83 mmol, 5.0 mol%), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (2.32 g, 11.6 mmol, 2.0 equiv), AgSbF_6 (400 mg, 2.0 mmol, 20 mol%) and 1,2-dichloroethane (20 mL). Then methyl acrylate **2a** (250mg, 0.255ml, 2.90 mmol, 0.5equiv) and diacetate **18** (1.0 g, 5.83 mmol, 1.0 equiv) were added into the solution in sequence. Then vial was sealed under N_2 and heated to 100 °C with stirring for 16 h. After cooling down, the mixture was diluted with ethyl acetate, filtrated and concentrated to give the crude compound which was directly purified by column chromatography (3:1: Pet ether : EtOAc) to give **19** (477 mg, 1.86 mmol, 32%).

(3Z,5E)-7-methoxy-7-oxohepta-3,5-diene-1,4-diyl diacetate (19)

^1H NMR (400 MHz, CDCl_3): δ 7.17 (d, J = 15.9 Hz, 1 H), 5.83 - 5.73 (m, 2 H), 4.13 (t, J = 6.7 Hz, 2 H), 3.75 (s, 3 H), 2.42 (q, J = 6.9 Hz, 2 H), 2.28 (s, 3 H), 2.05 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3): δ 171.0, 167.8, 166.7, 146.0, 138.7, 125.9, 117.7, 62.3, 51.8, 26.4, 20.9, 20.3. HRMS (ESI) m/z calcd. for $\text{C}_{12}\text{H}_{16}\text{O}_6$ [M+NH4]⁺ 274.1291; found 274.1296. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2954, 2849, 1765, 1738, 1652, 1627, 1435, 1368, 1309, 1238, 1198, 1172, 1037.

2.3b. Synthesis of compound 20




To a solution of **19** (450 mg, 1.75 mmol, 1.0 equiv) in methanol, added potassium carbonate (218 mg, 1.58 mmol, 0.9 equiv) in four portions over 5 min and reaction mixture was allowed to stirred for 40 minutes at room temperature. Then reaction mixture was quenched with water and extracted with ethyl acetate (15ml X 3), washed with brine, dried over anhydrous Na₂SO₄, concentrated *in vacuo* and purified by column chromatography (3 : 1.5 :: Pet ether : EtOAc) furnishing the compound **20** (262mg, 1.22mmol, 70%).

(E)-methyl 7-acetoxy-4-oxohept-2-enoate (20)

¹H NMR (400 MHz, CDCl₃): δ 7.08 (d, *J* = 16.0 Hz, 1 H), 6.70 (d, *J* = 16.0 Hz, 1 H), 4.10 (t, *J* = 6.3 Hz, 2 H), 3.82 (s, 3 H), 2.74 (t, *J* = 6.9 Hz, 2 H), 2.04 (s, 3 H), 2.02 - 1.97 (m, 2 H). ¹³C NMR (101 MHz, CDCl₃): δ 198.5, 171.1, 166.0, 139.3, 130.6, 63.4, 52.5, 38.0, 22.7, 21.0. HRMS (ESI) m/z calcd. for C₁₀H₁₄O₅ [M+Na]⁺ 237.0739; found 237.0730. IR (neat): ν_{max}/cm⁻¹ 2956, 2853, 1737, 1731, 1703, 1643, 1437, 1366, 1305, 1241, 1176, 1040.

2.3c. Synthesis of compound 21




Using a Dean-Stark trap, ethylene glycol (1.3 ml, 23.36 mmol, 30 equiv.) was refluxed in benzene (5 mL) for 1 hour. Upon cooling, compound **20** (250 mg, 1.16 mmol) in benzene (2 mL) and p-toluene sulfonic acid (10 mg, 0.046 mmol, 0.04 equiv.) were added to the solution and the resulting mixture was heated to reflux under a condenser for 1.5 hours (heating for more than 1.5 hours resulted in decomposition of product). The solution was then cooled and quenched with NaHCO₃ (10 mL). The resulting mixture was extracted with EtOAc (3 x 10 mL), washed with water (80 mL) and brine (80 mL), dried over Na₂SO₄ and concentrated. The crude product was purified by column chromatography (3 : 1.5:: Pet ether : EtOAc) to obtain of the pure ketal **21** (254 mg, 0.986 mmol, 85% yield) as a yellow liquid.

(E)-methyl 3-(2-(3-acetoxypropyl)-1,3-dioxolan-2-yl)acrylate (21)

¹H NMR (400 MHz, CDCl₃): δ 6.73 (d, *J* = 15.6 Hz, 1 H), 6.09 (d, *J* = 15.8 Hz, 1 H), 4.07 (t, *J* = 6.4 Hz, 2 H), 4.00 - 3.95 (m, 2 H), 3.90 - 3.85 (m, 2 H), 3.76 (s, 3 H), 2.04 (s, 3 H), 1.85 - 1.78 (m, 2 H), 1.78 - 1.70 (m, 2 H). ¹³C NMR (101 MHz, CDCl₃): δ 171.4, 166.9, 146.6, 121.9, 108.2, 65.3 (2C), 64.5, 52.1, 34.4, 22.8, 21.3. HRMS (ESI) m/z calcd. for C₁₂H₁₈O₆ [M+Na]⁺ 281.1001; found 281.1000. IR (neat): ν_{max}/cm⁻¹ 2955, 2895, 1731 (br.), 1663, 1436, 1387, 1365, 1305, 1243, 1197, 1169, 1036.

2.3d. Synthesis of compound 22




To a solution of **21** (240 mg, 0.930 mmol, 1.0 equiv) in methanol (8 ml), added dibutyl tin oxide (2.31 g, 5.9 mmol, 0.9 equiv) in one portion and reaction mixture was refluxed for 2 hours. Upon cooling the reaction mixture, concentrated *in vacuo*, solid was removed by filtration, residue washed with ethyl acetate and filterate was concentrated, purified by column chromatography (3 : 2 :: Pet ether : EtOAc) furnishing the product **22** (216 mg, 0.93 mmol, 90%) as a pale brownish liquid.

(E)-methyl 3-(2-(3-hydroxypropyl)-1,3-dioxolan-2-yl)acrylate (22)

¹H NMR (400 MHz, CDCl₃): δ 6.73 (d, *J* = 15.4 Hz, 1 H), 6.07 (d, *J* = 15.4 Hz, 1 H), 4.00 - 3.96 (m, 2 H), 3.89 - 3.85 (m, 2 H), 3.74 (s, 3 H), 3.63 (t, *J* = 5.9 Hz, 2 H), 2.03 (br. s., 1 H), 1.87 - 1.82 (m, 2 H), 1.69 - 1.64 (m, 2 H). ¹³C NMR (101 MHz, CDCl₃): δ 166.6, 146.3, 121.5, 108.1, 64.9 (2C), 62.5, 51.8, 34.1, 26.2. HRMS (ESI) m/z calcd. for C₁₀H₁₆O₅ [M+Na]⁺ 239.0895; found 239.0894. IR (neat): ν_{max}/cm⁻¹ 3400 (br.), 2954, 2849, 1765, 1738, 1652, 1627, 1435, 1368, 1309, 1238, 1198, 1172, 1037.

2.3e. Synthesis of norpyrenophorin 14³






Trimethylaluminium (0.925 mL of a 2 M solution, 1.85 mmol, 10 equiv) in toluene was added to a 5 mL side-arm flask containing selenium powder (150 mg, 1.924 mmol, 10.4 equiv) at 0 °C and refluxed till the selenium powder had reacted completely, the resulting mixture was cooled to room temperature. An aliquot of Me₂SeAlMe (10 µL, 1.1 mmol) was transferred by syringe to a solution containing compound **22** (40 mg, 0.185 mmol) in toluene (1.2 mL) at 0 °C. After 28 h of heating at reflux, the yellow solution was warmed to room temperature over a period of 30 min and treated with sodium sulfate. The solution was then diluted with dichloromethane, washed with water six times and treated with sodium hydrogen carbonate. The solution was then dried with brine and anhydrous magnesium sulfate. The solvent was removed under vacuum from the yellow solution and the residue was dissolved in acetone (0.75 mL), added p-toluene sulfonic acid (3 mg, 0.0081 mmol, 0.1 equiv) at 0 °C and stirred for 4 hours at room temperature. The reaction mixture was quenched with NaHCO₃ solution and extracted with EtOAc, dried over Na₂SO₄ and concentrated. The crude product was purified by column chromatography (1:1 : Pet ether : EtOAc) furnishing the **norprenophorin 14³** (6 mg, 0.0214 mmol, 23% in two steps).



Norpyrenophorin (14)



¹H NMR (500 MHz, CDCl₃): δ 7.03 (d, *J* = 16.3 Hz, 1 H), 6.68 (d, *J* = 16.2 Hz, 1 H), 4.31 (t, *J* = 5.9 Hz, 2 H), 2.85 (t, *J* = 7.0 Hz, 2 H), 2.13 - 2.07 (m, 2 H). ¹³C NMR (101 MHz, CDCl₃): δ 198.5, 165.4, 140.2, 131.2, 64.6, 37.2, 22.4. HRMS (ESI) m/z calcd. for C₁₄H₁₇O₆ [M+H]⁺ 281.1025; found 281.1025. IR (neat): ν_{max}/cm⁻¹ 2923, 2852, 1728, 1428, 1258.



3. NMR spectra

























































SKD1713-1H-6.JDF







SKD1710-13C-6.JDF












































































NAG1132A_PROTON-3 (2).JDF




6b


$$J_{\text{Ha-Hb}} = 20 \text{ Hz}$$

NAG1132A_CARBON-3 (2).JDF







NAG1140DP_PROTON-4 (3).JDF




NAG1140DP_CARBON-3 (1).JDF




NAG1127_PROTON-5 (1).JDF




NAG1127_13C-2.JDF




NAG1140C_1H-4 (2).JDF




NAG1140C_13C-3.JDF







NAG1126BPP_1H-4 (2).JDF







NAG1126BPP_13C-7 (3).JDF





















NAG545P_1H-4JDF







NAG545P_13C-4JDF



















4. References

1. Wang, J.; Ma, A.; Ma, D., Organocatalytic Michael Addition of Aldehydes to γ -Keto- α,β -unsaturated Esters. An Efficient Entry to Versatile Chiral Building Blocks. *Organic Letters* **2008**, *10* (23), 5425-5428.
2. Kowalczyk, R.; Wierzba, A. J.; Boratynski, P. J.; Bakowicz, J., Enantioselective conjugate addition of aliphatic thiols to divergently activated electron poor alkenes and dienes. *Tetrahedron* **2014**, *70* (35), 5834-5842.
3. Shen, L.-L.; Mun, H.-S.; Jeong, J.-H., Macrocyclisation of Macrodiolide with Dimethylaluminium Methaneselenolate. *Eur. J. Org. Chem.* **2010**, (36), 6895-6899, S6895/1-S6895/6.